J
Jedd D. Wolchok
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 795
Citations - 154490
Jedd D. Wolchok is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ipilimumab & Immune system. The author has an hindex of 140, co-authored 713 publications receiving 123336 citations. Previous affiliations of Jedd D. Wolchok include Ludwig Institute for Cancer Research & University of York.
Papers
More filters
Journal Article
ipilimumab Versus Placebo After Complete Resection Of Stage Iii Melanoma: Efficacy And Safety Results From The Eortc 18071 Phase Iii Trial : 374
Alexander M.M. Eggermont,Vanna Chiarion-Sileni,Jean J. Grob,Reinhard Dummer,Jedd D. Wolchok,Henrik Schmidt,Omid Hamid,Caroline Robert,Paolo A. Ascierto,Jon M. Richards,Virginia Ferraresi,Michael Smylie,Jeffrey S. Weber,Michele Maio,Cyril Konto,Veerle de Pril,Stefan Suciu,Alessandro Testori +17 more
Proceedings ArticleDOI
Abstract 4723: Targeting the IDO and TDO pathway through inhibition of the aryl hydrocarbon receptor
Jeremy H. Tchaicha,Karen McGovern,Luis Felipe Campesato,Silvia Coma,Xiaoyan Michelle Zhang,Meghan Walsh,Jill Cavanaugh,Taha Merghoub,Jedd D. Wolchok,Mark Manfredi +9 more
TL;DR: Data indicates that AHR is a viable target for reversing immune suppression in the tumor microenvironment and could have activity in many tumor types due to activation via kynurenine and multiple other potential ligands and enhanced tumor growth inhibition and survival benefit is seen in combination with checkpoint inhibitors.
Proceedings ArticleDOI
Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone
F. Stephen Hodi,Michael A. Postow,Jason Chesney,Anna C. Pavlick,Caroline Robert,Kenneth F. Grossmann,David F. McDermott,Gerald P. Linette,Nicolas Meyer,Jeffrey K. Giguere,Sanjiv S. Agarwala,Montaser Shaheen,Marc S. Ernstoff,David R. Minor,April K.S. Salama,Matthew H. Taylor,Linda Rollin,Christine Horak,Paul Gagnier,Jedd D. Wolchok +19 more
TL;DR: NIVO+IPI significantly improved ORR and PFS compared to IPI alone in treatment-naive pts with advanced melanoma, and had a manageable safety profile.
Journal ArticleDOI
Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC).
David B. Page,Jianda Yuan,Arielle Ginsberg,Zhiwan Dong,Phillip Wong,Ryan O. Emerson,Janice S. Sung,Christopher Comstock,Stephen B. Solomon,Virgilio Sacchini,Monica Morrow,Edi Brogi,Elizabeth A. Morris,Sujata Patil,Harlan Robins,Jedd D. Wolchok,Clifford A. Hudis,Larry Norton,James P. Allison,Heather L. McArthur +19 more
TL;DR: Cryo+ipi was more likely to induce systemic immune activation compared to cryo or ipi alone, and potentially beneficial immune effects were observed in both HR+ and HR- subtypes, as well as in tumors with low or high baseline TIL density.
Journal ArticleDOI
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Arvind Ravi,Matthew D. Hellmann,Monica Arniella,Mark Holton,Samuel S. Freeman,Vivek Naranbhai,Chip Stewart,Ignaty Leshchiner,Jaegil Kim,Yoshitaka Akiyama,Aaron T. Griffin,Natalie I. Vokes,Mustafa Sakhi,Vashine Kamesan,Hira Rizvi,Biagio Ricciuti,Patrick M. Forde,Valsamo Anagnostou,Jonathan W. Riess,Don L. Gibbons,Nathan A. Pennell,Vamsidhar Velcheti,Subba R. Digumarthy,Mari Mino-Kenudson,Andrea Califano,John V. Heymach,Roy S. Herbst,Julie R. Brahmer,Kurt A. Schalper,Victor E. Velculescu,Brian Henick,Naiyer A. Rizvi,Pasi A. Jänne,Mark M. Awad,Andrew Chow,Benjamin Greenbaum,Marta Luksza,Alice T. Shaw,Jedd D. Wolchok,Nir Hacohen,Gad Getz,Justin F. Gainor +41 more
TL;DR: In this article , a joint analysis of the Stand Up To Cancer-Mark Foundation cohort, a resource of whole exome and/or RNA sequencing from 393 patients with non-small cell lung cancer treated with anti-PD-(L)1/PD-L1 therapy, along with matched clinical response annotation is presented.